Aashni Shah

Ms. Aashni Shah

Polistudium srl, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
DRDaryl Ramai
Daryl Ramai
Antonio FacciorussoAntonio Facciorusso
Antonio Facciorusso
EVErika Vigandt
Erika Vigandt
BSBryan Schaf
Bryan Schaf
WSWaleed Saadedeen
Waleed Saadedeen
Rodolfo SaccoRodolfo Sacco
Rodolfo Sacco
Non-alcoholic steatohepatitis (NASH) is a chronic and progressive form of non-alcoholic fatty liver disease. Its global incidence is increasing and makes NASH an epidemic and a public health threat. Non-alcoholic fatty liver disease is associated with major morbidity and mortality, with a heavy burden on quality of life and liver transplant requirements. Due to repeated insults to the liver, patients are at risk for developing hepatocellular carcinoma. The progression of NASH was initially defined according to a two-hit model involving an initial development of steatosis, followed by a process of lipid peroxidation and inflammation. In contrast, current evidence proposes a “multi-hit” or “multi-parallel hit” model that includes multiple pathways promoting progressive fibrosis and oncogenesis. This model includes multiple cellular, genetic, immunological, metabolic, and endocrine pathways leading to hepatocellular carcinoma development, underscoring the complexity of this disease.

15 November 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
DRDaryl Ramai
Daryl Ramai
KDKhoi P. Dang-Ho
Khoi P. Dang-Ho
AKAnjali Kewalramani
Anjali Kewalramani
PBPraneeth Bandaru
Praneeth Bandaru
Rodolfo SaccoRodolfo Sacco
Rodolfo Sacco
Antonio FacciorussoAntonio Facciorusso
Antonio Facciorusso
Frailty represents a state of vulnerability to multiple internal physiologic factors, as well as external pressures, and has been associated with clinical outcomes. We aim to understand the impact of frailty on patients admitted with hepatocellular carcinoma (HCC) by using the validated Hospital Frailty Risk Score, which is implemented in several hospitals worldwide. We conducted a nation-wide retrospective cohort study to determine the effect of frailty on the risk of in-patient mortality, hepatic encephalopathy, length of stay and cost. Frailty was associated with a 4.5-fold increased risk of mortality and a 2.3-fold increased risk of hepatic encephalopathy. Adjusted Cox regression showed that frailty was correlated with increased risk of in-patient mortality (hazard ratio: 2.3, 95% CI 1.9–2.8, p < 0.001). Frail HCC patients had longer hospital stay (median 5 days) vs. non-frail HCC patients (median 3 days). Additionally, frail patients had higher total costs of hospitalization ($40,875) compared with non-frail patients ($31,667). Frailty is an independent predictor of hepatic encephalopathy and in-patient mortality. Frailty is a surrogate marker of hospital length of stay and cost.

15 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DRDaryl Ramai
Daryl Ramai
SDSmit S. Deliwala
Smit S. Deliwala
SCSaurabh Chandan
Saurabh Chandan
JLJanice Lester
Janice Lester
JSJameel Singh
Jameel Singh
Luca GiacomelliLuca Giacomelli
Luca Giacomelli
Acute porphyrias are a group of metabolic disorders resulting in defective porphyrin synthesis and reduced heme production, which carries a risk of malignancy. Porphyrias are inborn defects in the heme biosynthesis pathway resulting in neurovisceral manifestations and cutaneous photosensitivity attacks with multi-systemic involvement. Its estimated prevalence nears 5 per 100,000 patients worldwide. Subclinical liver disease is common, which can progress into transaminitis, fibrosis, cirrhosis, and malignancy. However, data on the incidence of primary liver cancer are lacking. We aim to determine the risk of hepatocellular carcinoma (HCC) in patients with porphyria. A systematic review and pooled analysis were conducted through 2021 on studies assessing blood tests, imaging, cancer development, liver transplant, surgical resection, and outcomes in porphyria. In total, 19 studies, which included 7381 patients with porphyria (3476 females), were considered for the final review. In eight studies, alpha-fetoprotein levels were elevated between 200 and 1000 IU/mL. Of the total cohort of patients with porphyria, primary liver cancer was diagnosed in 351 patients (4.8%), of whom 243 (3.3% of the total) were found to have HCC. A subset of patients was found to have cholangiocarcinoma (n = 18; 0.3% of the total). Interestingly, advanced liver disease or cirrhosis was not a prerequisite for the formation of HCC in a small group of patients. Of the total cohort, 30 patients underwent liver resection, 48 patients underwent liver transplantation, and 327 patients died. Patients with porphyria are at risk of developing primary liver malignancy. Further studies should aim to develop diagnostic and prognostic models aimed at the early detection of HCC in porphyria.

3 September 2020 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
ASAnna Santini
Anna Santini
IAIrene Avagnina
Irene Avagnina
ESEleonora Salamon
Eleonora Salamon
Luca GiacomelliLuca Giacomelli
Luca Giacomelli
ASAashni Shah
Aashni Shah
FBFranca Benini
Franca Benini

13 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DRDaryl Ramai
Daryl Ramai
SDSmit S. Deliwala
Smit S. Deliwala
SCSaurabh Chandan
Saurabh Chandan
JLJanice Lester
Janice Lester
JSJameel Singh
Jameel Singh
Luca GiacomelliLuca Giacomelli
Luca Giacomelli
We thank Dr. Lissing and colleagues for providing us with these helpful comments